Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
about
Adjuvant radiotherapy following radical prostatectomy for prostate cancerNeo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancerEvolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerCardiovascular effects of hormone therapy for prostate cancerCombination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyPharmacologic blockade and genetic deletion of androgen receptor attenuates aortic aneurysm formation.An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).Limits of observational data in determining outcomes from cancer therapy.Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapyRadiotherapy in prostate cancer treatment: results of the patterns of care study in KoreaObesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysisImpact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.Cancer, physical activity, and exerciseAdjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsLong-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactionsRadiation therapy in prostate cancer: a risk-adapted strategy.Androgen deprivation therapy for prostate cancer-review of indications in 2010Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience.National practice patterns and time trends in androgen ablation for localized prostate cancer.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Image-guided prostate cryosurgery: state of the art.A genetic basis for the variation in the vulnerability of cancer to DNA damage.Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy.Saudi Oncology Society clinical management guidelines for prostate cancer.Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.Hormone therapy in the management of prostate cancer: evidence-based approachesNeo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.Management of high-risk localized prostate cancer.Prostate cancer management: (1) an update on localised diseaseAdjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.What's a man to do? Treatment options for localized prostate cancer.The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
P2860
Q24234347-14356A5D-53DA-49C3-81D6-B6DADADCAC67Q24244156-5311A6CF-39B7-4DCD-A83C-9211591A8D48Q26744606-3B9500A9-EAEB-4988-BA1C-D4FCC86DE749Q26747782-45246705-6982-44A9-9F5C-2FAF621F1C6CQ26801112-9D559811-19B4-4819-A343-87F31B7E2025Q28218423-59422A8A-C158-44E5-B82E-7412A0AE0C74Q30277664-57268AD4-D7E6-494C-B7F6-4D33A596BA78Q30743682-3B380E09-7638-4CBE-B77B-AFD9BE329026Q31083661-99D19C37-C403-4AA4-9083-62A284CA6758Q31153256-71E4A60D-494A-4072-BC91-792770C4FA08Q33304413-1DBA82D6-0773-4810-A750-6AD1C8BD0D15Q33375063-6FC91B94-71E9-402C-8104-A40B1C842A38Q33583944-951062EA-88B2-4AF7-BAC3-17AC8578F33DQ33594364-0977BBF2-4CC6-44C8-822C-678D8564C292Q33613683-8F77F52F-D948-4369-91A4-7B28DF772A39Q33766974-F3EF68C7-AB9B-4BB9-AFAE-064B0CB92679Q34004946-366B4F60-B0F4-41EB-BFE8-CC277349F3EEQ34013808-85B08C26-C17D-49AC-AF32-F1E4A1DDC4C5Q34048625-BAC81A44-7A80-4F8C-B30A-0B96798E5CEBQ34048630-A0217700-A413-44C7-AF9D-65814D87DDDFQ34111590-47A41A67-8299-4207-8EE8-716CC18DB178Q34111603-5B23343D-3CCD-4DC3-8F8C-E780B5249064Q34171941-7B52811C-E781-409F-90F8-84D1FE9024BDQ34310143-6C7CA7E1-830A-41A7-AE80-2E835C35A82CQ34325452-EF2CAA4C-AAA0-4210-9B60-BCC213ACE61DQ34363769-7F9BC99F-81C8-4A04-95FD-43B3FD18BD74Q34417815-2245E07A-7B99-4E48-9259-D68ED006FF7DQ34437308-7684DF52-C7D3-48A8-93B8-99976896DBA3Q34504216-69E31C72-4898-4020-9B47-1E1573EB321DQ34523304-286015FB-DAFD-490B-AF22-6234DABB5618Q34984685-509E07AC-D84F-496F-B4A5-CBBD834BA8E8Q34997355-ACCF2331-46CC-44D4-8E4A-608248BD1A07Q35020521-6B079909-A605-494A-A8E3-F3A452BF47A4Q35076432-1F57DC74-F3B2-40C9-8713-0EE1C01F51A1Q35132144-3FB47D77-3B32-43F3-A055-B3BF392A4B50Q35503645-A0DAF061-2094-42AF-BF8F-4547235EA725Q35517935-1B15D1F4-CAF7-4537-AAC6-AF9B9CBCC93BQ35608929-E4B78FD0-1E5F-4020-9129-B5BF955E82E6Q35648211-23C64BB6-4427-4180-BD07-C4F2CEC0A0A8Q35680859-DDEF2A5C-DD48-4E5C-87D5-034EB3B5FC77
P2860
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Phase III radiation therapy on ...... ced carcinoma of the prostate.
@en
Phase III radiation therapy oncology group
@nl
type
label
Phase III radiation therapy on ...... ced carcinoma of the prostate.
@en
Phase III radiation therapy oncology group
@nl
prefLabel
Phase III radiation therapy on ...... ced carcinoma of the prostate.
@en
Phase III radiation therapy oncology group
@nl
P2093
P1476
Phase III radiation therapy on ...... ced carcinoma of the prostate.
@en
P2093
Pilepich MV
P304
P356
10.1016/S0360-3016(01)01579-6
P407
P577
2001-08-01T00:00:00Z